Bacil Pharma share news, announcements and annual reports
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 30 Oct 2026. Previous close ₹18.40.
30 Oct: open ₹18.50, high ₹18.99, low ₹18.40
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹27 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,126
Bacil Pharma share news and announcements
542 announcements, routine notices left out, newest first. Page 7 of 11.
Mar 2021
Feb 2021
5 Feb · Board meeting
Meeting on 13 Feb 2021: quarterly results
Jan 2021
21 Jan · Shareholding for the Period Ended December 31, 2020
Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click ....21 Jan · Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Nov 2020
24 Nov · Non Applicability Of Regulation 23(9)
12 Nov · Business
5 Nov · Board meeting
Meeting on 12 Nov 2020: quarterly results
Oct 2020
28 Oct · Compliance Certificate For The Half-Year Ended 30Th September 2020
22 Oct · Compliance Certificate From Practicing Company Secretary.
20 Oct · Shareholding for the Period Ended September 30, 2020
Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click ....20 Oct · Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 03 Oct · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Sep 2020
8 Sep · Reg. 34 (1) Annual Report
8 Sep · Board meeting
Meeting on 15 Sep 2020: quarterly results
Aug 2020
12 Aug · Non-Applicability Of Reg 23(9) For The Quarter And Year Ended 31St March, 2020
Jul 2020
30 Jul · Business
27 Jul · Board meeting
Meeting on 30 Jul 2020: audited results21 Jul · Shareholding for the Period Ended June 30, 2020
Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click ....20 Jul · Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
May 2020
27 May · Compliance Certificate Of Regulation 7(3) For The Half Year Ended, 31St March, 2020
26 May · PCS Certificate Under Regulation 40(10) For The Half Year 31St March, 2020
15 May · Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 07 May · Shareholding for the Period Ended March 31, 2020
Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click ....
Apr 2020
Mar 2020
27 Mar · Announcement under Regulation 30 (LODR)-Strikes /Lockouts / Disturbances
Feb 2020
3 Feb · Board meeting
Meeting on 8 Feb 2020: quarterly results